Chemistry:Aleglitazar
From HandWiki
Names | |
---|---|
Preferred IUPAC name
(2S)-2-Methoxy-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophen-7-yl}propanoic acid | |
Other names
Ro-0728804, R-1439
| |
Identifiers | |
3D model (JSmol)
|
|
ChEMBL | |
ChemSpider | |
DrugBank | |
KEGG | |
PubChem CID
|
|
UNII | |
| |
| |
Properties | |
C24H23NO5S | |
Molar mass | 437.51 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
verify (what is ?) | |
Infobox references | |
Tracking categories (test):
Aleglitazar is a peroxisome proliferator-activated receptor agonist (hence a PPAR modulator ) with affinity to PPARα and PPARγ, which was under development by Hoffmann–La Roche for the treatment of type II diabetes.[1] It is no longer in phase III clinical trials.[2]
References
- ↑ "Statement on a nonproprietary name adopted by the USAN Council: Aleglitazar". United States Adopted Names. American Medical Association. http://www.ama-assn.org/ama1/pub/upload/mm/365/aleglitazar.pdf.
- ↑ "Roche halts diabetes drug trial in blow to pipeline". Roche. 2013-07-10. https://www.reuters.com/article/us-roche-idUSBRE96903Z20130710.
Original source: https://en.wikipedia.org/wiki/Aleglitazar.
Read more |